Full history for every metric is available with a Kvantra account
Adcock Ingram Holdings Limited (AIP.JO)
Key financial summary
Financials in ZAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ZAR m | 7,347 | 7,777 | 8,706 | 9,132 | 9,643 | 9,760 | 9,760 |
| Operating profit | ZAR m | 1,076 | 1,145 | |||||
| Net profit | ZAR m | 676 | 657 | 800 | 898 | 814 | 859 | 859 |
| EPS reported | ZAR | 5.71 | 5.71 | |||||
| Operating cashflow per share | ZAR | 2.95 | 2.95 | |||||
| Capex per share | ZAR | 2.00 | 2.00 | |||||
| FCF per share | ZAR | 0.95 | 0.95 | |||||
| Free cash flow | ZAR m | 139 | 645 | |||||
| Net debt | ZAR m | -104 | -104 | |||||
| Book value equity | ZAR m | 5,833 | 5,833 | |||||
| Book value per share | ZAR | 38.81 | 38.86 | |||||
| Number of shares | m | 150.3 | 150.12 | |||||
| DPS (TTM paid) | ZAR | 1.65 | 2.80 |
Financial summary
Financials in ZAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 8.82 | - | |||||
| P/B LTM | x | 1.27 | 1.88 | |||||
| P/S LTM | x | 0.76 | 1.12 | |||||
| P/FCF LTM | x | 53.11 | 17.03 | |||||
| EV/EBITDA LTM | x | 5.11 | 9.99 | |||||
| EV/Sales LTM | x | 0.77 | 1.11 | |||||
| Earnings Yield LTM | % | 11.34% | 7.82% | |||||
| FCF Yield | % | 1.88% | 5.87% | |||||
| Quality | ||||||||
| ROE | % | 14.72% | 15.27% | |||||
| ROIC | % | 12.98% | 12.98% | |||||
| Operating margin | % | 11.03% | 11.03% | |||||
| Gross margin | % | 32.99% | 32.99% | |||||
| FCF/Sales | % | 1.43% | 1.43% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | +8.56% | +8.56% | |||||
| Sales Growth YoY | % | +1.22% | +1.22% | |||||
| Net Income Growth YoY | % | +5.47% | +5.47% | |||||
| FCF Growth | % | -82.94% | -82.94% | |||||
| Operating Profit Growth | % | +1.09% | +1.09% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 5.26% | 3.74% | |||||
| Dividend Growth | % | -37.74% | - | |||||
| Payout Ratio | % | 45.32% | 45.30% | |||||
| FCF/Debt | x | 0.57 | 2.64 | |||||
| Net Debt/EBITDA | x | 0.09 | 0.09 | |||||
| EBIT/Net interest | x | 9.05 | 9.05 | |||||
| Net debt/market cap | % | -1.41% | -0.95% | |||||
| Net debt/Equity | x | -0.02 | -0.02 | |||||
| Gross debt/equity | x | 0.04 | 0.04 | |||||
Company overview
Adcock Ingram Holdings Limited, established in 1890 and headquartered in Midrand, South Africa, operates as a global manufacturer, marketer, and distributor of diverse healthcare products. Its international footprint extends across South Africa, the United States, Canada, the United Kingdom, broader Europe, and other international regions. The company offers a comprehensive product portfolio, including over-the-counter (OTC) remedies, prescription medications, consumer health goods, and specialized medical instrumentation and surgical supplies. Its extensive pharmaceutical range covers numerous therapeutic classes, such as women's health, cannabidiol applications, antiretroviral treatments, dermatology, central nervous system disorders, respiratory conditions, ophthalmology, generic medicines, cardiovascular health, pain relief, gastroenterology, energy and immunity support (including colds and flu remedies, vitamins, minerals, and food/nutrition supplements), personal care, feminine hygiene, digestive well-being, allergy management, baby care, and cough solutions. Beyond its general healthcare offerings, Adcock Ingram also manufactures and supplies essential hospital and critical care products, such as intravenous solutions, renal dialysis systems, and blood collection supplies. The company serves both private and public sectors within the healthcare industry.
Similar companies
- Henan Taloph Pharmaceutical Stock Co.,Ltd
- Sun Pharma Advanced Research Company Limited
- Zhejiang AngLiKang Pharmaceutical CO.,LTD.
- Lionco Pharmaceutical Group Co.,Ltd.
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- IOL Chemicals and Pharmaceuticals Limited
- Hunan Fangsheng Pharmaceutical Co., Ltd.
- Hunan Hansen Pharmaceutical Co., Ltd.
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Adcock Ingram Holdings Limited (AIP.JO)
Adcock Ingram Holdings Limited, established in 1890 and headquartered in Midrand, South Africa, operates as a global manufacturer, marketer, and distributor of diverse healthcare products. Its international footprint extends across South Africa, the United States, Canada, the United Kingdom, broader Europe, and other international regions. The company offers a comprehensive product portfolio, including over-the-counter (OTC) remedies, prescription medications, consumer health goods, and specialized medical instrumentation and surgical supplies. Its extensive pharmaceutical range covers numerous therapeutic classes, such as women's health, cannabidiol applications, antiretroviral treatments, dermatology, central nervous system disorders, respiratory conditions, ophthalmology, generic medicines, cardiovascular health, pain relief, gastroenterology, energy and immunity support (including colds and flu remedies, vitamins, minerals, and food/nutrition supplements), personal care, feminine hygiene, digestive well-being, allergy management, baby care, and cough solutions. Beyond its general healthcare offerings, Adcock Ingram also manufactures and supplies essential hospital and critical care products, such as intravenous solutions, renal dialysis systems, and blood collection supplies. The company serves both private and public sectors within the healthcare industry.
- Henan Taloph Pharmaceutical Stock Co.,Ltd
- Sun Pharma Advanced Research Company Limited
- Zhejiang AngLiKang Pharmaceutical CO.,LTD.
- Lionco Pharmaceutical Group Co.,Ltd.
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- IOL Chemicals and Pharmaceuticals Limited
- Hunan Fangsheng Pharmaceutical Co., Ltd.
- Hunan Hansen Pharmaceutical Co., Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free